June 24, 2016 12:48pm

… The SCG&RT sector is trading down 42 of 43 covered companies and 1 up

Why is the market reacting in such an extreme manner? Nobody knows what to expect …

As the Russell is also rebalancing while global markets are ripped apart after the U.K. voted to leave the EU

Advise - TGIF, be opportunistic but, don’t rush into anything!

 

 

U.S. stocks traded sharply lower Friday in a global risk-off trade after Britain surprised markets by voting to leave the European Union.

The NASDAQ is DOWN -171.77 or -3.50% to 4,738.77 and the DOW is DOWN -501.09 or -2.78% to 17,509.98.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:    

  • The open was negative with an A/DL of 41/0 and 2 flats;
  • The mid-day stayed negative  with an A/DL of 41/1 and 1 flat;

 

 

Henry’omics:

U.S. stocks traded sharply lower Friday, reversing recent gains in a global risk-off trade after Britain surprised markets by voting to leave the European Union.

  • The Dow fell more than 500 points at the open; while the S&P 500 decline more than 2.5% lower. A historical note, the S&P 500 had opened 1.88% lower in 1986. The NASDAQ declined 154 points, or 3.15%.

The SCGT&RT sector opened negative and stayed negative at the mid-day.

 

 

Today’s Bottom Line:

Nearly every market’s downside moves has been attributed to the UK leaving the European Union.

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Friday traded <so far> above 23;
  • Thursday traded 17.4;
  • Wednesday topped 21;
  • Tuesday traded near 18.2;
  • Monday traded near 18;
  • Last, Friday traded near 19.3;

 

 

Who is UP:

  • Histogenics (HSGX) +$0.02 to $1.85 on 7,621 shares traded

Most negative sector stocks:

  • Neuralstem (CUR) -9.99%;
  • Biostage (BSTG) -8.18%;
  • Adverum (ADVM( -7.32%;
  • StemCells (STEM) -8.33%;
  • Osiris (OSIR) -5.86%

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.